You might also like
Novanta Inc. is a global supplier of core technology solutions that empower medical and advanced industrial original equipment manufacturers (OEMs) with precision and performance. The company specializes in engineering components and subsystems for demanding applications, leveraging expertise in photonics, vision, and precision motion technologies. Novanta's offerings cater to critical markets such as healthcare, robotics, and advanced manufacturing.
-
Medical Solutions - Develops and supplies medical insufflators, pumps, visualization solutions, video processing technologies, touch panel displays, and machine vision systems for minimally invasive surgery, medical imaging, and patient monitoring.
- Sub-products: RFID technologies, barcode identification systems, thermal chart recorders, and light/color measurement devices.
-
Precision Medicine and Manufacturing - Provides photonics-based solutions, including laser scanning systems, laser beam delivery, CO2 lasers, solid-state lasers, ultrafast lasers, and optical light engines for advanced industrial processes, medical imaging, and DNA sequencing.
-
Robotics and Automation - Offers optical and inductive encoders, precision motors, servo drives, motion control solutions, integrated stepper motors, robotic end-of-arm technology, and air bearing spindles for robotics, automation, and microelectronics applications.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Matthijs Glastra ExecutiveBoard | Chair of the Board & CEO | None | CEO since 2016, Chair since 2021. Over 25 years of leadership experience in OEM-based technology businesses. Previously held leadership roles at Philips. | View Report → |
John Burke Executive | Chief Accounting Officer (CAO) | None | CAO since 2024. Previously VP of Global Accounting at Novanta. CPA with prior experience at MilliporeSigma and PwC. | |
Michele D. Welsh Executive | General Counsel & Corporate Secretary | None | Joined Novanta in 2022. Previously held senior legal roles at Carlisle Companies and Aon plc. | |
Robert J. Buckley Executive | Chief Financial Officer (CFO) | None | CFO since 2011. Oversees financial operations. Previously held financial leadership roles at other organizations. | |
Barbara B. Hulit Board | Director | Board Member at Envista Holdings Corporation and PACCAR Inc.; Dean’s Advisory Council at Kellogg School of Management | Director since 2022. Former CEO of Advanced Healthcare Solutions at Fortive. Expertise in business strategy, innovation, and M&A. | |
Darlene J.S. Solomon Board | Director | Board Member at Materion Corporation | Director since 2022. CTO at Agilent Technologies. Member of the National Academy of Engineering. Expertise in R&D and technology innovation. | |
Frank A. Wilson Board | Director | Board Member at Alkermes plc and Cabot Corporation | Director since 2021. Former CFO at PerkinElmer. Expertise in financial management and corporate governance. | |
Lonny J. Carpenter Board | Lead Director | Board Member at Merit Medical Systems, The Boler Company, and Orchid Orthopedics Solutions | Director since 2018, Lead Director since 2021. Former Group President at Stryker Corporation. Extensive experience in global quality and operations. | |
Mary Katherine Ladone Board | Director | None | Director since 2024. Appointed to fill a vacancy. No additional details provided in the documents. | |
Maxine L. Mauricio Board | Director | EVP, Chief Administrative Officer, General Counsel & Secretary at EMCOR Group; Dartmouth College Committees | Director since 2020. Chair of Novanta's ESG Committee. Extensive legal and compliance expertise. | |
Thomas N. Secor Board | Director | Managing Director at Morningside Heights Capital | Director since 2012. Extensive experience in strategic transactions, corporate finance, and governance. |
-
Your precision medicine and manufacturing segment experienced a 15% sales decline in Q3, with adjusted gross margins down due to lower factory utilization ; what specific steps are you taking to mitigate the impact of this decline on overall company margins, and how confident are you in a rebound in 2025 given the current market dynamics ?
-
Given that nearly all shipments of your DNA sequencing products originally expected in Q4 have been rescheduled to 2025 due to customer challenges , how are you addressing the risks associated with customer delays, and what assurances do you have that these delays won't extend further into 2025 ?
-
Despite deferring approximately $25 million in revenue into 2025, your guidance for 2025 remains at up to 10% organic growth ; can you elaborate on why the deferred revenue isn't translating into a higher growth rate for 2025, and whether there are other factors offsetting this potential increase ?
-
With the decremental gross margin in your precision medicine and manufacturing segment being almost 100% due to maintaining fixed costs despite lower volumes , what is your strategy to improve margins if volume recovery in 2025 is slower than anticipated ?
-
You've mentioned that macroeconomic and geopolitical uncertainties are causing customers to defer purchases ; how resilient is your business model to prolonged uncertainties, and what contingency plans do you have if the anticipated market recovery in 2025 does not materialize as expected ?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Motion Solutions Parent Corp. | 2024 | The acquisition was completed on January 2, 2024 for $192.0 million in cash, financed using borrowings under Novanta’s revolving credit facility, enhancing its precision motion control and medical capabilities within the Medical Solutions segment. |
Motion Solutions | 2023 | Announced on November 14, 2023 with an expected close in Q1 2024, this planned acquisition is valued at $189 million in cash and is aimed at strengthening Novanta's position in precision motion control and the medical and life sciences sectors, anticipating significant revenue impact and strategic market expansion. |
MPH Medical Devices S.R.O. | 2022 | Completed on August 11, 2022 at an approximate cost of €21.8 million ($22.4 million), this acquisition expands Novanta’s manufacturing capacity for disposable medical consumables, integrates into its Minimally Invasive Surgery (MIS) business, and is expected to improve its margin profile and strategic market presence. |
Recent press releases and 8-K filings for NOVT.
- Q1 2025 GAAP revenue reached $233M (up approximately 1-2% from prior year) .
- GAAP diluted EPS rose to $0.59 and net income increased by 45% to $21.2M, with adjusted EBITDA at $50.0M and operating cash flow of about $32M .
- Achieved a 46% adjusted gross margin alongside robust cash flow performance in Q1 2025 .
- Completed its first 2025 acquisition by acquiring Kion, an RFID and AI-enhanced solution provider, to drive strategic expansion .
- Management implemented effective tariff mitigation strategies, with near-term Q2 guidance trending at the high end ($240M) .